-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QDpR8smb4PFJ4FIsWMd9cxtr08uHXYcWboUf80XHLhvwGzEIUSpO4J/Bvkr7cRuW xiYUNCEas+HXDoTakXU85A== 0001144204-09-057720.txt : 20091110 0001144204-09-057720.hdr.sgml : 20091110 20091110102057 ACCESSION NUMBER: 0001144204-09-057720 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090930 FILED AS OF DATE: 20091110 DATE AS OF CHANGE: 20091110 EFFECTIVENESS DATE: 20091110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 091170624 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v165005_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: September 30, 2009 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. November 5, 2009 - -------------------------- --------------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 56 ----------- Form 13F Information Table Entry Value: 1,529,025 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 3-31-2009
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ---------------------------- ------- ------- ------- --- ---- ---------- -------- ---- ------ ---- Acorda Therapeutics COM 00484M106 27,792 1,193,821 SH SOLE 1,193,821 Adolor Corp. COM 00724X102 7,191 4,522,772 SH SOLE 4,522,772 Allos Therapeutics Inc. COM 019777101 42,282 5,832,002 SH SOLE 5,832,002 Alsius Corp. COM 021211107 3 62,872 SH SOLE 62,872 Amicus Therapeutics COM 03152W109 6,677 763,097 SH SOLE 763,097 Amylin Pharmaceuticals COM 032346108 17,423 1,272,700 SH SOLE 1,272,700 Anadys Pharmaceuticals Inc. COM 03252Q408 355 134,792 SH SOLE 134,792 AP Pharma COM 00202J203 2,452 2,884,546 SH SOLE 2,884,546 Aradigm Corp. COM 038505301 18 100,000 SH SOLE 100,000 Ardea Biosciences Inc. COM 03969P107 94,328 5,146,589 SH SOLE 5,146,589 Autoimmune Inc. COM 052776101 37 13,050 SH SOLE 13,050 Auxilium COM 05334D107 156,665 4,579,518 SH SOLE 4,579,518 Biocryst Pharmaceuticals Inc. COM 09058V103 45,844 5,563,615 SH SOLE 5,563,615 Cadence Pharmaceuticals COM 12738T100 7,036 636,215 SH SOLE 636,215 Chelsea Therapeutics COM 163428105 3,417 1,361,263 SH SOLE 1,361,263 Cornerstone BioPharma COM 22674T105 736 112,337 SH SOLE 112,337 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 132 92,311 SH SOLE 92,311 Dendreon Corp. COM 24823Q107 19,637 701,579 SH SOLE 701,579 Depomed COM 249908104 800 183,145 SH SOLE 183,145 Genomic Health Inc. COM 37244C101 125,615 5,572,425 SH SOLE 5,572,425 Halozyme Therapeutics Inc. COM 40637H109 14,003 1,969,512 SH SOLE 1,969,512 Human Genome COM 444903108 30,827 1,637,988 SH SOLE 1,637,988 Icagen Inc. COM 45104P104 47 46,373 SH SOLE 46,373 Idera Pharmaceuticals Inc. COM 45168K108 1,609 217,136 SH SOLE 217,136 Immunogen Inc. COM 45253H101 2,954 364,279 SH SOLE 364,279 Immunomedics, Inc. COM 452907108 263 47,704 SH SOLE 47,704 Incyte Corp. COM 45337C102 89,146 13,173,417 SH SOLE 13,173,417 Infinity Pharmaceuticals Inc. COM 45665G303 1,377 220,973 SH SOLE 220,973 Inhibitex Inc. COM 45719T103 622 620,904 SH SOLE 620,904 Inspire COM 457733103 18,835 3,608,190 SH SOLE 3,608,190 Intermune Inc. COM 45884X103 23,461 1,472,782 SH SOLE 1,472,782 Inverness Medical COM 46126P106 53,962 1,393,286 SH SOLE 1,393,286 Metabasis Therapeutics Inc. COM 59101M105 866 2,018,903 SH SOLE 2,018,903 Micromet COM 59509C105 19,950 2,995,608 SH SOLE 2,995,608 Neurogen Corp. COM 64124E106 1,942 8,205,406 SH SOLE 8,205,406 Onyx COM 683399109 5,994 200,000 SH SOLE 200,000 Pharmasset Inc. COM 71715N106 1,906 90,147 SH SOLE 90,147 Pharmathene COM 71714G102 3,411 838,175 SH SOLE 838,175 Salix Pharmaceuticals, Inc. COM 795435106 102,079 4,801,442 SH SOLE 4,801,442 Seattle Genetics Inc. COM 812578102 224,063 15,970,287 SH SOLE 15,970,287 Senomyx COM 81724Q107 137 34,114 SH SOLE 34,114 Sucampo CLASS A 864909106 375 64,387 SH SOLE 64,387 Supergen COM 868059106 885 331,480 SH SOLE 331,480 Targacept COM 87611R306 11,334 530,355 SH SOLE 530,355 Threshold Pharma COM 885807107 2,724 1,504,711 SH SOLE 1,504,711 Torreypines Therapeutics COM 89235K105 8 33,546 SH SOLE 33,546 Trimeris Inc. COM 896263100 8,543 3,461,175 SH SOLE 3,461,175 Via Pharmaceuticals COM 92554T103 35 102,881 SH SOLE 102,881 Viropharma Inc. COM 928241108 90,486 9,405,977 SH SOLE 9,405,977 Xenoport Inc. COM 98411C100 8,570 403,695 SH SOLE 403,695 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 22,050 23,465,000 N PR SOLE 23,465,000 Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 CONV BONDS 09061GAD3 10,645 10,000,000 N PR SOLE 10,000,000 Human Genome 2.25% 10/15/11 CONV BONDS 444903AK4 8,994 6,500,000 N PR SOLE 6,500,000 Incyte Genomics Notes 4.75% 10/1/2015 CONV BONDS 45337CAH5 169,800 160,000,000 N PR SOLE 160,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 27,757 27,313,000 N PR SOLE 27,313,000 Intermune Inc Notes 5% 3/1/15 CONV BONDS 45884XAD5 10,925 10,000,000 N PR SOLE 10,000,000
-----END PRIVACY-ENHANCED MESSAGE-----